HNN3.0
Register
Register
Register

Project cooperationUpdated on 19 January 2026

New Approach Methodologies: patient-derived iPSC models

full professor at Department of Pharmaceutical Sciences, University of Latvia

Riga, Latvia

About

We have expertise in patient-derived iPSC generation and differentiation into skeletal myoblasts and myotubes for rare muscular dystrophies, including LGMDR1. Our work focuses on preclinical disease modelling to support personalised therapeutic development. We seek participation in a Horizon Europe consortium developing antisense oligonucleotide or base-editing approaches for rare inherited muscle diseases, contributing relevant cellular models for target validation and preclinical testing.

Topic

  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

Type

  • Partner seeks Consortium/Coordinator

Similar opportunities

  • Project cooperation

    Providing validated in vivo functional assays, electrophysiology and pharmacology expertise to strengthen NAMs, rare disease and ATMP consortia

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Henri Leinonen

    Research Director, Research Council of Finland Fellow at University of Eastern Finland School of Pharmacy

    Kuopio, Finland

  • Project cooperation

    ELSI, regulatory and methodological aspects of pharmacological, clinical and data science research

    • Partner seeks Consortium/Coordinator
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Lucia Ruggieri

    Researcher at Fondazione per la ricerca farmacologica Gianni Benzi onlus

    ITALIA (IT), Italy

  • Project cooperation

    Cardiovascular Preclinical Model Expertise for Horizon Europe Health Consortia

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Roisin Kelly-Laubscher

    Senior Lecturer and Principal Investigator at University College Cork

    Cork, Ireland